In SSc, TGF-β1 independently activates JAK2 and STAT3 via SMAD3, and pharmacologic or genetic inactivation of JAK2 in skin reduces the profibrotic effects of TGF-β1 [8]. This evidence concerns the gene SMAD3 and systemic sclerosis.